edoc

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review) : report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Goodin, D. S. and Cohen, B. A. and O'Connor, P. and Kappos, L. and Stevens, J. C. and Therapeutics, and Technology, Assessment Subcommittee of the American Academy of Neurology. (2008) Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review) : report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, Vol. 71, H. 10. pp. 766-773.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6007476

Downloads: Statistics Overview

Abstract

The clinical and radiologic impact of natalizumab (Tysabri) as therapy for multiple sclerosis (MS) is assessed. On the basis of Class I evidence, natalizumab has been demonstrated to reduce measures of disease activity and to improve measures of disease severity in patients with relapsing-remitting (RR) MS (Level A). The relative efficacy of natalizumab compared to current disease-modifying therapies cannot be defined accurately (Level U). Similarly, the value of natalizumab in the treatment of secondary progressive (SP) MS is unknown (Level U). The value of combination therapy using natalizumab and interferon in the treatment of RRMS is also unknown (Level U). There is an increased risk of developing progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients (Level A for combination therapy, Level C for monotherapy) and possibly an increased risk of other opportunistic infections (Level C). The PML risk in a pooled clinical trial cohort has been estimated to be 1 person for every 1,000 patients treated for an average of 17.9 months, although this figure could change in either direction with more experience with the drug.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
UniBasel Contributors:Kappos, Ludwig
Item Type:Article, refereed
Article Subtype:Further Journal Contribution
Bibsysno:Link to catalogue
Publisher:Lancet Publications
ISSN:0028-3878
Note:Publication type according to Uni Basel Research Database: Journal item
Related URLs:
Identification Number:
Last Modified:20 Jun 2014 07:55
Deposited On:20 Jun 2014 07:55

Repository Staff Only: item control page